{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:08:36Z","timestamp":1791173316244,"version":"4.1.0"},"reference-count":28,"publisher":"EDP Sciences","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Sci (Paris)"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1051\/medsci\/200925121085","type":"journal-article","created":{"date-parts":[[2011,3,3]],"date-time":"2011-03-03T10:02:37Z","timestamp":1299146557000},"page":"1085-1089","source":"Crossref","is-referenced-by-count":8,"title":["Anticorps monoclonaux th\u00e9rapeutiques en oncoh\u00e9matologie"],"prefix":"10.1051","volume":"25","author":[{"given":"Guillaume","family":"Cartron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"250","published-online":{"date-parts":[[2009,12,15]]},"reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Feugier P, Van Hoof A, Sebban C,et al.Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma : a study by the Groupe d\u2019\u00e9tude des lymphomes de l\u2019adulte.J Clin Oncol2005; 23 : 4117\u201326.","DOI":"10.1200\/JCO.2005.09.131"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Hiddemann W, Kneba M, Dreyling M,et al.Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone : results of a prospective randomized study of the german low-grade lymphoma study group.Blood2005; 106 : 3725\u201332.","DOI":"10.1182\/blood-2005-01-0016"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Herold M, Haas A, Srock S,et al.Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma : an East German study group hematology and oncology Study.J Clin Oncol2007; 25 : 1986\u201392.","DOI":"10.1200\/JCO.2006.06.4618"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Marcus RE, Solal-Celigny P, Imrie K,et al.MabThera (Rituximab) plus cyclophosphamide, vincristine and prednisone (R-CVP) chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkin\u2019s lymphoma (NHL).Blood2006; 108 : 481a.","DOI":"10.1182\/blood.V108.11.481.481"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Salles G, Mounier N, de Guibert S,et al.Rituximab combined with chemotherapy and interferon in follicular lymphoma patients : results of the GELA-GOELAMS FL2000 study.Blood2008; 112 : 4824\u201331.","DOI":"10.1182\/blood-2008-04-153189"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Van Oers MH, Klasa R, Marcus RE,et al.Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction : results of a prospective randomized phase 3 intergroup trial.Blood2006; 108 : 3295\u2013301.","DOI":"10.1182\/blood-2006-05-021113"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Forstpointner R, Unterhalt M, Dreyling M,et al.Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas : results of a prospective randomized study of the German low grade lymphoma study group (GLSG).Blood2006; 108 : 4003\u20138.","DOI":"10.1182\/blood-2006-04-016725"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"O\u2019Brien SM, Kantarjian H, Thomas DA,et al.Rituximab dose-escalation trial in chronic lymphocytic leukemia.J Clin Oncol2001; 19 : 2165\u201370.","DOI":"10.1200\/JCO.2001.19.8.2165"},{"key":"R9","unstructured":"James DF, Castro JE, Sandoval-Sus JD,et al.Rituximab and high-dose methylprednisolone for the initial treatment of chronic lymphocytic leukemia is associated with promising clinical activity and minimal hematologic toxicity.Blood2008; 112 : 47."},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Witzig TE, Flinn IW, Gordon LI,et al.Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma.J Clin Oncol2002; 20 : 3262\u20139.","DOI":"10.1200\/JCO.2002.11.017"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Witzig TE, Gordon LI, Cabanillas F,et al.Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma.J Clin Oncol2002; 20 : 2453\u201363.","DOI":"10.1200\/JCO.2002.11.076"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Morschhauser F, Radford J, Van Hoof A,et al.Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.J Clin Oncol2008; 26 : 5156\u201364.","DOI":"10.1200\/JCO.2008.17.2015"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Kaminski MS, Tuck M, Estes J,et al.131I-tositumomab therapy as initial treatment for follicular lymphoma.N Engl J Med2005; 352 : 441\u20139.","DOI":"10.1056\/NEJMoa041511"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Press OW, Unger JM, Braziel RM,et al.Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin\u2019s lymphoma : five-year follow-up of Southwest oncology group protocol S9911.J Clin Oncol2006; 24 : 4143\u20139.","DOI":"10.1200\/JCO.2006.05.8198"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Keating MJ, Flinn I, Jain V,et al.Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine : results of a large international study.Blood2002; 99 : 3554\u201361.","DOI":"10.1182\/blood.V99.10.3554"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Hillmen P, Skotnicki AB, Robak T,et alAlemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.J Clin Oncol2007; 25 : 5616\u201323.","DOI":"10.1200\/JCO.2007.12.9098"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Burnett AK, Kell WJ. The addition of gemtuzumab ozogamycin toinduction therapy for AML improves disease free survival without extra toxicity.Blood2006; 108 : 13.","DOI":"10.1182\/blood.V108.11.13.13"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Maloney DG, Grillo-Lopez AJ, Bodkin DJ,et al.IDEC-C2B8 : results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin\u2019s lymphoma.J Clin Oncol1997; 15 : 3266\u201374.","DOI":"10.1200\/JCO.1997.15.10.3266"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Maloney DG, Liles TM, Czerwinski DK,et al.Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.Blood1994; 84 : 2457\u201366.","DOI":"10.1182\/blood.V84.8.2457.2457"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside : ways to improve rituximab efficacy.Blood2004; 104 : 2635\u201342.","DOI":"10.1182\/blood-2004-03-1110"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Cartron G, Dacheux L, Salles G,et al.Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene.Blood2002; 98 : 754\u20138.","DOI":"10.1182\/blood.V99.3.754"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Salles G, Morschhauser F, Cartron G,et al.A Phase I\/II study of RO5072759 (GA101) in patients with relapsed\/refractory CD20+malignant disease.Blood2008; 112 : 234.","DOI":"10.1182\/blood.V112.11.234.234"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Bibeau F, Crapez E, Di Fiore F,et al.Association of FcgRIIa and FcgRIIa polymorphisms with clinical outcome in metastatic colorectal cancer patients (mCRC) treated with cetuximab and irinotecan.J Clin Oncol2008; 26 : 11004.","DOI":"10.1200\/jco.2008.26.15_suppl.11004"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Musolino A, Naldi N, Bortesi B,et al.Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of Trastuzumab-based therapy in patients With HER-2\/neu\u2013positive metastatic breast cancer.J Clin Oncol2008; 26 : 1789\u201396.","DOI":"10.1200\/JCO.2007.14.8957"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses.Nat Rev Immunol2008; 8 : 34\u201347","DOI":"10.1038\/nri2206"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Loisel S, Ohresser M, Pallardy M,et al.Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment.Crit Rev Oncol Hematol2007; 62 : 34\u201342.","DOI":"10.1016\/j.critrevonc.2006.11.010"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Cartron G, Zhao-Yang L, Baudard M,et al.Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma : results of a phase II study.J Clin Oncol2008; 26 : 2725\u201331.","DOI":"10.1200\/JCO.2007.13.7729"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Lobry C, Weil R. New Bcl10 regulation mechanisms : a step in the comprehension of what has occurred in MALT lymphomas\u00a0?Med Sci (Paris)2007; 23 : 353\u20135.","DOI":"10.1051\/medsci\/2007234353"}],"container-title":["m\u00e9decine\/sciences"],"original-title":[],"link":[{"URL":"http:\/\/www.medecinesciences.org\/10.1051\/medsci\/200925121085\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T19:21:08Z","timestamp":1637349668000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.medecinesciences.org\/10.1051\/medsci\/200925121085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":28,"journal-issue":{"issue":"12"},"alternative-id":["medsci20092512p1085"],"URL":"https:\/\/doi.org\/10.1051\/medsci\/200925121085","relation":{},"ISSN":["0767-0974","1958-5381"],"issn-type":[{"value":"0767-0974","type":"print"},{"value":"1958-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}